Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as CYCLE. It is marketed under 1 brand name, including TASCENSO ODT. Available in 2 different strengths, such as EQ 0.25MG BASE, EQ 0.5MG BASE, and administered through 1 route including TABLET, ORALLY DISINTEGRATING;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"88859","ingredient":"FINGOLIMOD LAURYL SULFATE","trade_name":"TASCENSO ODT","family_id":"3e651a23d81c4bc9ae7a","publication_number":"US10555902B2","cleaned_patent_number":"10555902","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-01-19","publication_date":"2020-02-11","legal_status":"Patented case"} | US10555902B2 | 11 Feb, 2020 | Patented case | 19 Jan, 2036 | |
{"application_id":"88867","ingredient":"FINGOLIMOD LAURYL SULFATE","trade_name":"TASCENSO ODT","family_id":"3e651a23d81c4bc9ae7a","publication_number":"US10925829B2","cleaned_patent_number":"10925829","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-01-19","publication_date":"2021-02-23","legal_status":"Patented case"} | US10925829B2 Formulation | 23 Feb, 2021 | Patented case | 19 Jan, 2036 | |
{"application_id":"88866","ingredient":"FINGOLIMOD LAURYL SULFATE","trade_name":"TASCENSO ODT","family_id":"3e651a23d81c4bc9ae7a","publication_number":"US9925138B2","cleaned_patent_number":"9925138","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-01-19","publication_date":"2018-03-27","legal_status":"Patented case"} | US9925138B2 Formulation | 27 Mar, 2018 | Patented case | 19 Jan, 2036 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Fingolimod Lauryl Sulfate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.